The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism

Author： Kalinowski Danuta S.   Jansson Patric J.   Kovacevic Zaklina   Richardson Des R.  

Publisher： Maney Publishing

ISSN： 1743-2928

Source： Redox Report, Vol.18, Iss.2, 2013-03, pp. : 48-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CD4+CD25+ Regulatory T-Cell Therapy for Allergy, Autoimmune Disease and Transplant Rejection

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 5, Iss. 4, 2006-12 ,pp. : 239-242

Bentham Science Publishers

Access to resources Recommend Favorite

The Impact of Immunosuppressive Drugs on the Analysis of T-Cell Activation

By  

Current Medicinal Chemistry, Vol. 7, Iss. 7, 2000-07 ,pp. : 673-692

Bentham Science Publishers

Access to resources Recommend Favorite

Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 4, 2009-12 ,pp. : 328-343

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting T-Cell Adhesion Molecules for Drug Design

By  

Current Pharmaceutical Design, Vol. 12, Iss. 22, 2006-08 ,pp. : 2797-2812

Bentham Science Publishers

Access to resources Recommend Favorite

Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses

By  

Current Drug Targets, Vol. 17, Iss. 6, 2016-05 ,pp. : 630-639

Bentham Science Publishers

Access to resources Recommend Favorite